SCHEMBL25835254

SCHEMBL25835254

CCCC(=O)N[C@H]1C(OCc2ccc(O)cc2)O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ PYGB P11216 1/20 0.48
▸ SLC5A1 P13866 3/20 0.46
▸ SLC5A2 P31639 2/20 0.46
▸ SSTR1 P30872 1/20 0.44
▸ SSTR2 P30874 1/20 0.44
▸ SSTR4 P31391 1/20 0.44
▸ SSTR3 P32745 1/20 0.44
▸ SSTR5 P35346 1/20 0.44
▸ MCHR1 Q99705 3/20 0.43
▸ SLC28A3 Q9HAS3 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ TYR P14679 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21058378 0.91 CA1 (0.48) CA1CA2CA9MAPK1PYGB
SCHEMBL21058354 0.91 CA1 (0.51) CA1CA2CA9MAPK1PYGB
SCHEMBL21137915 0.84 CA1 (0.48) CA1CA2CA9MAPK1PYGB
SCHEMBL21137864 0.84 PYGB (0.59) CA1CA2CA9MAPK1PYGB
SCHEMBL10958757 0.83 MAPK1 (0.55) CA1CA2CA9MAPK1SSTR3
SCHEMBL10958752 0.83 MAPK1 (0.55) CA1CA2CA9MAPK1SSTR3
SCHEMBL21058364 0.83 SSTR3 (0.55) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL8652701 0.81 SLC6A2 (0.48) CA1CA2CA9POLBKDM4E
SCHEMBL21138263 0.79 MAPK1 (0.70) CA1CA2CA9MAPK1PYGB
SCHEMBL21058342 0.78 SSTR3 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA CA1 3104/4885CA2 4331/4885CA9 2393/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA CA1 3238/4885CA2 3597/4885CA9 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback